Jefferies Starts Coverage on Cellectis, Assigns Buy and $7 Target
Jefferies has initiated coverage of Cellectis (NASDAQ:CLLS) with a Buy rating and a $7.00 price objective, representing an 88% uplift from the stock's current level of $3.73. The firm characterizes the company as "largely overlooked" given an enterprise value near $60 million, even as Cellectis has posted robust revenue growth and demonstrated enco…